Sun, Oct 26, 2014, 2:27 AM EDT - U.S. Markets closed


% | $
Quotes you view appear here for quick access.

Insmed Incorporated Message Board

  • mike75x5 mike75x5 Feb 19, 2014 8:50 AM Flag

    UBS price target unchanged at $31.00!

    ...... until I see proof otherwise. This along with Piper upgrade, Will's comments, and today's news should get things moving again. New 52 week high?

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • $20 by March 1.

      Sentiment: Buy

    • Hey Mike, This is what I got from IR withing the last week.

      "While it is disappointing to have an analyst who was previously positive on the Company, reverse his position based on no news from the Company, it remains the prerogative of the individual analyst to express his/her opinion and the Company will not make a public comment on this. The Company’s Directors are aware of the Wedbush rating change. Please note that UBS, Canaccord Genuity, HC Wainwright, Leerink Swann and Piper Jaffray analysts all continue to maintain their positive outlooks for Insmed with no changes to rating or price targets.

      While this downgrade may have affected the share price in the near term, it is the long term value of the Company that is important. Hopefully, the Company’s upcoming data from the U.S. Phase 2 trial of ARIKACE to treat NTM lung disease will be positive, and Insmed will continue to move forward to bring this important therapeutic to NTM patients suffering from this debilitating lung disease for which there are no currently approved treatments.

      Best regards,

      Anne Marie

      As you can see, there was no indication that UBS had downgraded

14.27-0.06(-0.42%)Oct 24 3:59 PMEDT

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.